Welcome, Guest
Username: Password: Remember me
General
  • Page:
  • 1

TOPIC: dear, Marc --

dear, Marc -- 14 Feb 2016 22:16 #6378

  • angryharry
  • angryharry's Avatar Topic Author
  • Offline
  • Junior Boarder
  • Junior Boarder
  • Posts: 35
  • Thank you received: 3
i invested in you because i believe your intentions are good and because you're not inspired by money. i invested in you because i believed in my heart that you were doing your best to help people rather than rob them. i'm telling you now that you and your voice with a name (CFO) better start delivering results before i start an unintentional stroke of anger.

Please Log in or Create an account to join the conversation.

dear, Marc -- 15 Feb 2016 05:06 #6379

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3358
  • Thank you received: 1116
You might also say....Houston, we have a problem..

DOV comments after having had the topic on his mind for 5 days or so was...

I did have plenty of time to think about the OA press release and even had an e-mail exchange with Tiago. Given the current situation with the stock in the tank and a delisting event approaching, the press release was by far the worst on record. The 24 week ACT-OA results were one of our last hopes for new investors to come into the stock and perhaps lift the stock to a higher equilibrium price. Instead, the wording chosen by Dr. Marc Hedrick caused a complete misinterpretation of the data (if one wants to call it data) and a 25% drop in the stock price. Everyone read the results as being a failing trial.


My partner- who apparently will get a visit from Hedrick/Girao next week, is seething from the quality of the OA announcement and totally disgusted with the usual generosity of rewarding themselves for no performance, which already has been an issue for 15 years and enraged me personally tremendously in the past...at present I am simply receptive and indifferent, since I have come to terms with their greed :bash:

Personally - I do not know the man and would like it to keep it that way, since I tend to be a softie and change my mind occasionally. Other folks I have spoken to- who have owned million of shares in the time frame that we did not have the toxic dilution, describe Marc as a very honest-, but extremely careful and conservative MD, who cares for the sick and weak.

That is all fine and wonderful, but for me that is not the profile for a CEO leading us into the future participating in a "shark infested" market. I believe Marc totally when he writes, that he is very pleased with the OA results, but if the market rewards the announcement with a 25% drop in market cap and share price, we have a problem.... :whistle:

Houston - do something... :evil: :bang:
The following user(s) said Thank You: Joncon63, d9dozrman, fatboy

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

dear, Marc -- 15 Feb 2016 06:44 #6381

  • CalhounDoppelganger
  • CalhounDoppelganger's Avatar
  • Offline
  • Gold Boarder
  • Gold Boarder
  • Posts: 160
  • Thank you received: 20
The board needs to reposition Hedrick to chief medical officer and then appoint a real savvy businessman as ceo. We need a wheeler and dealer that has tentacles all over United States congress.

If the BOD does not act, the wheels will be put in motion to make it happen at the ballot box

Please Log in or Create an account to join the conversation.

dear, Marc -- 15 Feb 2016 07:44 #6382

  • franshei
  • franshei's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 790
  • Thank you received: 103
Like myself, Marc Hedrick is not a CEO type. However, he is not suitable to be the Chief Medical Officer. Kesten is more seasoned. Hedrick cannot do Kesten's job to set up and monitor clinical studies and interact with the FDA medical officer. He has been in the so-called management position for too long and he is out of touch with the real medical affairs in the pharma/biotech industry. He can only serve as a member on the board of directors.

After Hedrick became CEO, CYTX has lost 90% of its value and the market cap went from over $ 250 million to less than $ 30 million. In many other biotechs, the CEOs have to take the blame and be replaced with someone who can turn things around.

Hedrick has to go! His departure can precipitate a rally, even in the face of a pending r/s ( I think share holders' approval notice will come out in late April/early May - there will be a lot of fight before this can be approved and this is why Hedrick and Tiago are going around talking to big investors, who have lost a lot of real money).

Without a r/s, I think this company can go under.

Please Log in or Create an account to join the conversation.

dear, Marc -- 15 Feb 2016 10:26 #6388

  • fatboy
  • fatboy's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 416
  • Thank you received: 77

Without a r/s, I think this company can go under


Why would a reverse split save the company? It does not create any value and would only increase the possibility of more shorting. De-listing is inevitable unless the scleroderma results come soon and are stellar. A reverse split will only screw the current shareholders again.

Please Log in or Create an account to join the conversation.

dear, Marc -- 15 Feb 2016 10:46 #6390

  • rothco619
  • rothco619's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 467
  • Thank you received: 67
I agree. I am against R/S as they don't work out and I do believe that opens the door for short attack. History has proven that to be true as that is exactly what happened when price was inflated to keep from de listing last time. I don't think Marc & Tiago will listen to that reasoning and will R?S much to dismay of long term holders. To me where stock is listed at this point in time it is a pink sheet stock, anyway you spin it. leave it alone, deliver some results and the pps will take care of itself. reverse split will kill it.

Please Log in or Create an account to join the conversation.

dear, Marc -- 15 Feb 2016 11:20 #6392

  • franshei
  • franshei's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 790
  • Thank you received: 103
Roth, without a r/s, CYTX will be delisted. With a one for 15 r/s, CYTX will be back to over $1 and CYTX can do ATM with occasional good news. If there is no r/s, where would the money be coming from? Japan and MAP money is still far off from May 31.

I am sure you have discussed w Hedrick re r/s and where would they get the next $ 20 million.

The current burn rate is about $6 M/Q and at the end of 2015, the company should have $ 13 M cash. By mid-year, even if the burn rate is down to $ 4 M/Q, the cash reserve would be down to below $ 5 M. Where can they raise the money to float the company? If they are selling shares at 10 cents per share, the dilution for $ 20 M will flood the shares outstanding.

Please Log in or Create an account to join the conversation.

dear, Marc -- 15 Feb 2016 11:44 #6394

  • rothco619
  • rothco619's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 467
  • Thank you received: 67
That is a most interesting question, and one that they did not provide an answer for which was quite puzzling . For a company that is in dire need of cash they were not as concerned as we are.
While I had many questions answered that one remained a mystery. I believe there are investors out there that would fund and invest more, but not unless we see a solid tangible result, and not more unfulfilled promises. Hope and prayer does not work for me. I asked if you are to be profitable by 2018 how do you plan to make it that long, and the answer to that question remains a mystery. There better be a unexpected surprise and fast. I won't be holding my breath, as I will suffocate for sure. Holding out hope but that's it for now. Not going to throw any more money after this pipe dream unless there is a major change of fortune :bash:

Please Log in or Create an account to join the conversation.

dear, Marc -- 15 Feb 2016 11:46 #6396

  • CalhounDoppelganger
  • CalhounDoppelganger's Avatar
  • Offline
  • Gold Boarder
  • Gold Boarder
  • Posts: 160
  • Thank you received: 20
I'm trying to think of companies that were delisted to otc/pink sheets and regained financial footing enabling them to relist on an exchange.

I wonder if this is even an option, rather than to reverse split only to get hammered by shorts once more?

We have a pipeline. We have pivotal phase 3. Is it that far fetched to delist, get sub $0.10 and rise from the ashes ?

Please Log in or Create an account to join the conversation.

dear, Marc -- 15 Feb 2016 12:01 #6397

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3358
  • Thank you received: 1116

CalhounDoppelganger wrote: I'm trying to think of companies that were delisted to otc/pink sheets and regained financial footing enabling them to relist on an exchange.

I wonder if this is even an option, rather than to reverse split only to get hammered by shorts once more?

We have a pipeline. We have pivotal phase 3. Is it that far fetched to delist, get sub $0.10 and rise from the ashes ?


I am pretty sure that happened with ATCT i.e. Ocata. I think they came back on Nassie early 2015. Surely Joey will know and he is getting his money from Astellas now, since Astellas gained majority ownership a few days ago after a 3 months fight with thousands of disgruntled shareholders... :yawn:

Does that remind anyone of another case? :evil: and by coincidence the last toxic finance done by Mizuho for most likely also a few shareholders in the land of the Rising Sun where SC Companies are now "in vogue" especially against depressed prices. :bash:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

dear, Marc -- 15 Feb 2016 12:19 #6398

  • franshei
  • franshei's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 790
  • Thank you received: 103
CC

There are many examples in biotech, rising from pink sheet into NASDAQ.

One of my favorite example is NEOP (it has a different symbol now; also a medical device company). Company failed its NDA/BLA application and the company was delisted, because its stockholders would not approve a r/s. With about 50 million shares outstanding, the company struggled for couple of years with only $ 300K cash only 3 employees, then it started to rise from 6 to 7 cents (from a previous peak around $ 6 to 7 per share) to over $ 5 (from pink sheet to NASDAQ). The stock prospered during the 2008/2009 mini depression. Why? They had a small phase 3 trial, leading into NDA/BLA.

In the case of CYTX, the number of shares outstanding is too big for a very small company (200 million shares) and the number of employees are too many (the overhead is too big).

Please Log in or Create an account to join the conversation.

dear, Marc -- 15 Feb 2016 12:41 #6399

  • cytxer
  • cytxer's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 347
  • Thank you received: 25

fatboy wrote:

Without a r/s, I think this company can go under


Why would a reverse split save the company? It does not create any value and would only increase the possibility of more shorting. De-listing is inevitable unless the scleroderma results come soon and are stellar. A reverse split will only screw the current shareholders again.



A 40 RS brings you back to 5 million and 6 $ ish. Then you dilute and dilute all the way to 50 million shares again (my rough guestimate) then You might "get there" in 2-5 years... Guess what is the value of your Pre R/S shares THEN. About a penny or two (todays count)..... This is the best case scenario, assuming we all can hit the jackpot and be the one in a million company who made it back...

Put some casino odds on that one when you dream to doctor's lullaby :nice:

Please Log in or Create an account to join the conversation.

dear, Marc -- 15 Feb 2016 13:17 #6400

  • franshei
  • franshei's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 790
  • Thank you received: 103
This is what XOMA has done and it has multiple cycles of failure, due to clinical study disasters (lack of statistical significance)

XOMA is an antibodies biotech, 25 years old. It has many successes, when the out licensed antibodies are developed by other companies. Xoma has not been able to bring a single drug out to NDA stage by itself.

Yet, the company wanted to do its own clinicals. The stock was a decent $ 3 + stock. Then it had exact the same fate as CYTX, sinking to the teens (below 20 cents), after failures here and there (no ends in sight at the time). I think after one for 15 or so r/s, the outstanding shares were shrunk from over 200 million (I think 300 million) to 20 million (?), the company has been able to live on for another 3 + years. During this time, the company keeps on diluting the outstanding shares back to 100 million plus, using shares as currency. Then, more clinical failures. XOMA is now a penny stock again.

Although most of us think the scleroderma interim data is good. It is good because of its unmet clinical use and initial pain relief. Actually, the return of pain in the later stage of the clinical evaluation is worrisome, suggesting more clinical improvement may be needed, such as multiple injections over time and maybe local together with systemic injection may improve the clinical outcome.

When I look at the OSIR technology platform and some of its clinical scopes, they would scare us. They can easily extend the clinical scope into scleroderma, using off shelf clinical vials. To them, scleroderma maybe too limited to go after. But, again many developing SC companies are competing in several common and somewhat related indications. Money is key for some to reach the destinations.

Please Log in or Create an account to join the conversation.

dear, Marc -- 15 Feb 2016 13:57 #6401

  • fatboy
  • fatboy's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 416
  • Thank you received: 77

A 40 RS brings you back to 5 million and 6 $ ish. Then you dilute and dilute all the way to 50 million shares again (my rough guestimate) then You might "get there" in 2-5 years... Guess what is the value of your Pre R/S shares THEN. About a penny or two (todays count).....


As PT Barnum once said - "There is a sucker born every day" I think the tit is dry on this one. Of course a stem cell treatment would probably cure that problem. :grin:

Please Log in or Create an account to join the conversation.

dear, Marc -- 15 Feb 2016 17:30 #6402

  • cytxer
  • cytxer's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 347
  • Thank you received: 25

franshei wrote: This is what XOMA has done and it has multiple cycles of failure, due to clinical study failures.

XOMA is an antibodies biotech, 25 years old. It has many successes, when the out licensed antibodies are developed clinically by other companies. Xoma has not been able to bring a single drug out to NDA stage by itself.

Yet, the company wanted to do its own clinicals. The stock was a decent $ 3 + stock. Then it had exact the same fate as CYTX, sinking to the teens, after failures here and there (no ends in sight). I think after one for 15 or so r/d, the outstanding shares were shrunk form over 200 million (I think 300 million) to 20 million (?), the company is able to live on for another 3 + years. During this time, the company keeps on diluting the outstanding shares back to 100 million plus, using shares as currency. Then, more clinical failures. XOMA is now a penny stock again.

Athough most of us think the scleroderma interim data is good. It is good because of its unmet clinical use and initial pain relief. Actually, the return of pain in the later stage of the clinical evaluation is worrisome, suggesting more clinical improvement may be needed, such multiple injections over time and maybe local and systemic injections may improve the clinical outcome.

When I look at the OSIR technology platform and some of its clinical application scopes, they would scare us. They can easily extend the clinical scope into scleroderma, using off shelf clinical vials. To them, scleroderma maybe too limited to go after. But, again many developing SC companies are competing in several common and somewhat related indications. Money is key for some to reach the destinations.



You are all grown up now :cry:

There will be lots of growing pain in this industry, which pioneers seldom win. (I think Chris and Marc will, but CYTX probably won't).

Please Log in or Create an account to join the conversation.

dear, Marc -- 15 Feb 2016 17:36 #6403

  • cytxer
  • cytxer's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 347
  • Thank you received: 25

fatboy wrote:

A 40 RS brings you back to 5 million and 6 $ ish. Then you dilute and dilute all the way to 50 million shares again (my rough guestimate) then You might "get there" in 2-5 years... Guess what is the value of your Pre R/S shares THEN. About a penny or two (todays count).....


As PT Barnum once said - "There is a sucker born every day" I think the tit is dry on this one. Of course a stem cell treatment would probably cure that problem. :grin:


:grin:


***"There is a sucker born every day"*** Very true. live and learn, I guess.
The following user(s) said Thank You: fatboy

Please Log in or Create an account to join the conversation.

dear, Marc -- 16 Feb 2016 10:17 #6406

  • fatboy
  • fatboy's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 416
  • Thank you received: 77
cytxr wrote:

live and learn, I guess


I just wish it wasn't such an expensive lesson! And you know what - I am still learning. These guys are teaching me something new every day!

Please Log in or Create an account to join the conversation.

dear, Marc -- 17 Feb 2016 14:47 #6421

  • joeycav11
  • joeycav11's Avatar
  • Offline
  • Expert Boarder
  • Expert Boarder
  • Posts: 130
  • Thank you received: 41
Hi Fas, ACTC/Ocata was never fully listed until about a yr ago. Before that it had always been on Nasdaq OTC.
Oh and we got burned big time with that takeover.The company never did release the trial results 2 years after completion of trail (And we know they were amazing) Furthermore a PIVOTAL phase 2 trial was approved in England for children with blindness....Stargards.... it was never started. So much other news was also never released.
They knew they were selling the company 18 months ago

Please Log in or Create an account to join the conversation.

  • Page:
  • 1
Time to create page: 0.110 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites